Mutation in Cutaneous Lymphoma Linked to Poor Prognosis

Article

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma who have a MYD88 mutation have a shorter disease-specific survival.

Micrograph of DLBCL, lymph node FNA specimen, field stain; source: Nephron, Wikimedia Commons

A new study confirms that patients with primary cutaneous diffuse large B-cell lymphoma, leg type (PCLBCL-LT) who have a MYD88 mutation have a shorter disease-specific survival compared with patients without the mutation.

Anne Pham-Ledard, MD, of Universitaire Bordeaux, Bordeaux, France, and colleagues confirmed this association in a retrospective multicenter study of medical records from 61 patients with PCLBCL-LT diagnosed between 1988 and 2010.

“Next-generation sequencing studies identified recurring and multiple genetic alterations implicated in the oncogenesis of nodal ABC-DLBCL, contributing to the nuclear factor-κB pathway constitutive activity,” Pham-Ledard and colleagues wrote in JAMA: Dermatology. “Notably, mutations affecting the B-cell receptor signaling pathway (CD79B) and other proteins affecting the nuclear factor-κB signaling most commonly, mutations of MYD88, CARD11, and TNFAIP3/A20 have been reported.”

Pham-Ledard sought to determine if any clinical features or outcomes were associated with MYD88 status. The median age of the patients examined was 79 years and 59% were women. Fifty-eight patients were ultimately included in the study group.

Results of the analysis showed that 59% of patients had the MYD88 L265P mutation. Although patients with and without the mutation had similar characteristics at presentation, those with the mutation were more likely to be older (P = .006), and had more frequent involvement of the leg (P = .008). No differences in sex, number of skin lesions, TNM stage at diagnosis, and treatment regimens were found.

Patients with the MYD88 mutation were also shown to have shorter 3-year (65.7% vs 85.4%) and 5-year specific survival rates (60.2% vs 71.7%) compared with patients with the wild-type allele.

In addition, patients with the mutations had a shorter disease-specific survival rates in both univariate (P = .03) and multivariate analysis (P = .02).

“Mutation of MYD88 predicts a poorer outcome considering MYD88 signaling and nuclear factor-κB pathway activation as actionable targets,” the researchers wrote. “Therapeutic strategies targeting either B-cell receptor signaling (as ibrutinib, the Bruton tyrosine kinase inhibitor, or fostamatinib targeting the spleen tyrosine kinase), or the interferon regulatory factor-4 and the transcription factor Spi-B (targeted by lenalidomide), or NF-κB proteasome inhibitor (bortezomib), or MYD88 inhibitors, seem promising in ABC-DLBCL and especially in PCLBCL-LT.”

Recent Videos
Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
Preliminary phase 2 trial data show durvalumab plus lenalidomide was superior to durvalumab alone in refractory/advanced cutaneous T-cell lymphoma.
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Related Content